A Smart + Strong Site
Subscribe to:
E-newsletters
POZ magazine
JOIN AIDSMEDS YouTube

Back to home » Treatment News » Top Stories

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
A 15-Year Jump in Life Expectancy for People With HIV
Life Expectancy for Young People With HIV Is Nearly Normal
Failure to Awaken Dormant Cells Deals Blow to HIV Cure Research
Scientists Devise Method of Snipping HIV From Immune Cells
Media Cooks Up Claim That Soy Sauce Treats, Even Cures HIV
FDA Approves New Single-Tablet HIV Regimen, Triumeq
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


emailprint

June 13, 2013

Pre-Exposure Prophylaxis Protects Drug Users Against HIV

Prescribing an antiretroviral (ARV) to HIV-negative injection drug users, a practice known as pre-exposure prophylaxis (PrEP), cuts in half their risk of acquiring the virus, The New York Times reports. Furthermore, those who did the best at adhering to the PrEP regimen saw a three-quarters reduction in risk. The Centers for Disease Control and Prevention (CDC) sponsored the research in Thailand that yielded these results, which complete an optimistic portrait of PrEP’s efficacy. Tenofovir, the active agent in PrEP, can now officially lower risk for all the main groups at risk of becoming infected with HIV: injection drug users, babies of HIV-positive mothers, gay and bisexual men as well as heterosexuals.

“This is a significant step forward for HIV prevention. We now know that PrEP can work for all populations at increased risk for HIV,” Jonathan Mermin, MD, director of CDC’s division of HIV/AIDS prevention, said in a release. “Injection drug use accounts for a substantial portion of the HIV epidemic around the world, and we are hopeful that PrEP can play a role in reducing the continued toll of HIV infection in this population.”

Called the Bangkok Tenofovir Study, the research was conducted by a partnership through the CDC, the Bangkok Metropolitan Administration and the Thailand Ministry of Public Health. They studied more then 2,400 adults at 17 Bangkok drug-treatment clinics. The participants were randomly assigned to take a daily dose of tenofovir or a placebo. Everyone in the study also received HIV prevention counseling, monthly HIV testing and a risk-reduction package addressing both sexual and drug-related risk factors.

A total of 17 participants among the 1,204 taking tenofovir became infected with HIV, while 33 participants of the 1,207 taking the placebo acquired the virus, meaning that PrEP yielded a 49 percent reduction in risk of infection for the group.

Some of those in the study chose to be monitored taking their therapy. The researchers conducted a separate analysis of those members of this group who took tenofovir at least 71 percent of the days and who did not miss more than two days in a row. They found that these more-adherent participants had a 74 percent reduction of risk.

“These findings add to the mounting scientific evidence that high adherence to PrEP is essential to achieve the greatest benefit,” Mermin said. “When used consistently and in conjunction with other proven prevention measures, PrEP can provide important additional protection for many people who remain at high risk for HIV, including those who inject drugs.”

To read the New York Times story, click here.

To read the CDC’s press release on the study, click here.

Search: PrEP, pre-exposure prophylaxis, tenofovir, IDU, injection drug users, Thailand, Jonathan Mermin, Centers for Disease Control and Prevention, CDC, Bangkok Tenofovir Study


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)


[Go to top]

Quick Links
AIDSmeds en Español
About HIV and AIDS
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
Health Services Directory
POZ Magazine


    chipper52
    Palm Springs
    California


    newlife202
    JOLIET
    Illinois


    sefarady
    New York
    California


    clintonjrsyr
    syracuse
    New York
Click here to join POZ Personals!
Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014


21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014


7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013


more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.